Skip to main content
. 2022 Jan 20;2(1):39–48. doi: 10.1158/2767-9764.CRC-21-0032

FIGURE 4.

FIGURE 4

PFS in PD-L1–high versus PD-L1–low/negative durvalumab-treated patients at different IC-based cut-off points. Kaplan–Meier plots of PFS for cut-off points of IC1% (A), IC10% (B), and IC25% (C). IC, immune cell; PD-L1, programmed cell death ligand-1; PFS, progression-free survival.